Optimizing Dosing Strategies in Oral Iron Supplementation
Key facts
- Who runs it
- Luzerner Kantonsspital
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 29 people enrolled
- Started
- 1 Mar 2024
- Ended
- 18 Nov 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tardyferon
- Record updated
- 7 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Informed Consent signed by the subject
- ≥18 years of age
- Iron deficiency: Ferritin <30 µg/l
- hemoglobin ≥ 80 g/l
- CRP < 5 mg/l
Who cannot take part
- Oral or intravenous iron supplementation <12 weeks prior to investigation
- Blood transfusion or donation <12 weeks prior to investigation
- Active chemotherapy
- Contraindications to intervention medication (Tardyferon), e.g. known hypersensitivity or allergy to iron sulfate / ferrous sulfate
- Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject; Note; Due to slow recruitment, the following inclusion criterion was removed on 09/25/2024 (MM/DD/YYYY):; Anemia (as defined by the WHO): Hemoglobin <130 g/L for men, Hemoglobin <120 g/l for women, Hemoglobin <110 g/l for pregnant women
- Refusal of study participation,
- Regular administration of Erythropoietin
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate, if a change in dosing strategy in oral iron supplementation from leads to an improvement of iron absorption and consequently a faster therapy in patients with iron deficiency.
Read full original descriptionShow less
The main question the study aims to answer is: Does a treatment effect (measured by change in hemoglobin after 12 weeks of treatment) exist between daily oral iron supplementation and interval administration (every second day)? Participants will receive oral iron supplementation every second day with double the standard dose (intervention group). Researchers will compare this group with the active control group, that receives oral iron supplementation every day with the standard dose.
Participants will present for three patient visits (at baseline, after 6 and after 12 weeks of treatment).
The 2 groups in the trial
- Intervention GroupTreatment being tested
Oral iron supplementation with Eisen-II-Sulfat (Tardyferon ®) Every second day 2 x 80 mg Tardyferon® for a duration of 12 weeks.
Treatment: Tardyferon
- Active ControlExisting treatment, for comparison
Oral iron supplementation with Eisen-II-Sulfat (Tardyferon ®) Every day 1x 80 mg Tardyferon® for a duration of 12 weeks
Treatment: Tardyferon
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 7 January 2026